Salud financiera de hoja de balance de Intervacc

Salud financiera controles de criterios 5/6

Intervacc tiene un patrimonio de los accionistas total de SEK180.4M y una deuda total de SEK115.0K, lo que sitúa su ratio deuda-patrimonio en 0.06%. Sus activos y pasivos totales son SEK205.0M y SEK24.6M respectivamente.

Información clave

0.06%

Ratio deuda-patrimonio

SEK 115.00k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 49.30m
Patrimonio	SEK 180.40m
Total pasivo	SEK 24.60m
Activos totales	SEK 204.99m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK63.7M) de 2E9 superan a sus pasivos a corto plazo (SEK24.5M).

Pasivo a largo plazo: Los activos a corto plazo de 2E9 (SEK63.7M) superan a sus pasivos a largo plazo (SEK115.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 2E9 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 2E9 ha pasado de 0.1% a 0.06% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 2E9 tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 2E9 tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 11.4% cada año

Salud financiera de hoja de balance de Intervacc

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings released: kr1.69 loss per share (vs kr1.28 loss in FY 2022)

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

New major risk - Shareholder dilution

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.13 loss in 1Q 2021)

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings released: kr0.59 loss per share (vs kr0.55 loss in FY 2020)

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Forecast to breakeven in 2022

Forecast to breakeven in 2023

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

Forecast breakeven pushed back to 2023

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

Independent Director recently sold €2.9m worth of stock

New 90-day high: €7.54

Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)

Intervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021

Intervacc AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day high: €5.55

Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for Strangvac

Third quarter 2020 earnings released: kr0.13 loss per share

New 90-day high: €3.91

New 90-day high: €3.57

First half earnings released

New 90-day high - €3.43

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera